Loading...
XASXPAB
Market cap5mUSD
Dec 27, Last price  
0.00AUD
1Q
-33.33%
Jan 2017
-30.92%
IPO
-99.25%
Name

Patrys Ltd

Chart & Performance

D1W1MN
XASX:PAB chart
P/E
—
P/S
5.90
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
13.69%
Rev. gr., 5y
10.55%
Revenues
1m
-51.11%
003,7354,6547,5994,8512,643759,6832,224,481274,97053,263520,525844,36527,50027,50027,5002,851,9081,394,163
Net income
-4m
L-49.88%
0-7,323,602-8,662,339-7,535,123-7,421,670-5,108,891-3,529,095-7,289,090-8,470,382-1,080,784-1,057,876-2,497,252-411,326-2,748,539-4,062,920-6,780,363-7,061,624-3,539,150
CFO
-2m
L-68.58%
-7,454,956-7,258,356-7,054,679-5,113,507-3,754,504-2,627,920-5,089,233-4,114,778-1,531,357-1,276,981-2,086,722-129,185-2,495,525-3,877,157-8,679,213-5,778,822-1,815,937
Earnings
Feb 21, 2025

Profile

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company also focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer. In addition, it is developing PAT-DX3, a full-sized antibody that has DNA-binding and DNA damage repair blocking properties of PAT-DX1 used for tissue distribution, pharmacokinetic profile, etc.; and PAT-DX1-NP, a product based on the targeted delivery of nanoparticles carrying therapeutic payloads to the inside of cancer cells. The company was incorporated in 2006 and is based in Melbourne, Australia.
URL
https://patrys.com/
IPO date
Jul 13, 2007
Employees
15
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
1,394
-51.11%
2,852
10,270.57%
28
0.00%
Cost of revenue
4,933
9,861
8,049
Unusual Expense (Income)
NOPBT
(3,539)
(7,009)
(8,021)
NOPBT Margin
Operating Taxes
(1,285)
(2,775)
(4,787)
Tax Rate
NOPAT
(2,254)
(4,234)
(3,234)
Net income
(3,539)
-49.88%
(7,062)
4.15%
(6,780)
66.88%
Dividends
Dividend yield
Proceeds from repurchase of equity
4
6
7,211
BB yield
-0.03%
-0.03%
-18.39%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(2,241)
(4,046)
(7,818)
Cash flow
Cash from operating activities
(1,816)
(5,779)
(8,679)
CAPEX
(3)
(2)
Cash from investing activities
1,007
1,000
1,994
Cash from financing activities
4
6
7,556
FCF
(739)
(1,462)
(3,763)
Balance
Cash
2,241
4,046
7,818
Long term investments
Excess cash
2,171
3,903
7,816
Stockholders' equity
3,470
6,838
13,427
Invested Capital
1,302
2,935
5,611
ROIC
ROCE
EV
Common stock shares outstanding
2,055,750
2,055,402
1,960,626
Price
0.01
-30.00%
0.01
-50.00%
0.02
-64.29%
Market cap
14,390
-29.99%
20,554
-47.58%
39,213
-56.69%
EV
12,150
16,509
31,395
EBITDA
(3,492)
(6,962)
(7,974)
EV/EBITDA
Interest
Interest/NOPBT